Compare Aecom (ACM) vs Baxter International Inc (BAX) Price & Performance

ACM trades at $75.84, up 1.21% daily, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings missed expectations with a loss of $0.50 per share, though revenue trends remain stable near $16 billion annually. The company secured new infrastructure projects in Australia and Portugal, supporting a record backlog. Valuation metrics show a P/E of 15.83 and P/S of 0.63, below sector averages, indicating potential undervaluation.

Outlook is mixed: strong analyst consensus (64% buy) and a $99.20 price target suggest 31% upside, but Q2 miss and rising debt-to-asset ratio (22.61% in 2025) pose risks. Investors should weigh robust contract wins against earnings volatility and macroeconomic pressures on infrastructure spending.

Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.

The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.